Cargando…
Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk
Ibrutinib is the first clinically approved inhibitor of Bruton’s tyrosine kinase, an enzyme that is essential for survival and proliferation of B‑cells by activating the B‑cell receptor signalling pathway. Ibrutinib has been shown to be highly effective in B‑cell malignancies in clinical trials and...
Autores principales: | Stühlinger, Markus C., Weltermann, Ansgar, Staber, Philipp, Heintel, Daniel, Nösslinger, Thomas, Steurer, Michael |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035304/ https://www.ncbi.nlm.nih.gov/pubmed/31414181 http://dx.doi.org/10.1007/s00508-019-1534-1 |
Ejemplares similares
-
Dabigatran in patients with atrial fibrillation: perioperative and periinterventional management
por: Weltermann, A., et al.
Publicado: (2012) -
Direct Oral Anticoagulants in Asian Patients with Atrial Fibrillation: Consensus Recommendations by the Asian Pacific Society of Cardiology on Strategies for Thrombotic and Bleeding Risk Management
por: Chong, Daniel TT, et al.
Publicado: (2021) -
Recommendations for Management of Equine Athletes with Cardiovascular Abnormalities
por: Reef, V.B., et al.
Publicado: (2014) -
Management Recommendations on Sleep Disturbance of Patients with Parkinson's Disease
por: Liu, Chun-Feng, et al.
Publicado: (2018) -
Updated Recommendations on Cardiovascular Prevention in 2022: An Executive Document of the Italian Society of Cardiovascular Prevention
por: Volpe, Massimo, et al.
Publicado: (2022)